GlycoMira is a company that develops synthetic glycosaminoglycan-based therapeutics that modulate the innate immune molecules. Its technology has the potential to address significant unmet needs for radiation oncology and chronic respiratory indications.
GlycoMira has demonstrated safety and efficacy of its lead drug candidate against a broad spectrum of inflammatory diseases with private investments, Utah state, and federal government grant awards from the National Institutes of Health. The company's current drug development is focused on Oncology and Respiratory disease indications.
GlycoMira is developing a new class of glycosaminoglycan-based therapeutics that modulate the innate immune response and have the potential to address various unmet medical needs especially in cancer and respiratory diseases.GlycoMira's proprietary synthetic glycosaminoglycans and its lead candidate drug GM-1111 reduce mucosal inflammations caused by various inducers, such as radiation, allergen, or microbial exposure.